A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Jang, Min Hye ^a,b   Kim, Hyun Jung ^a   Chung, Yul Ri ^c   Lee, Yangkyu ^a   Park, So Yeon ^a,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Yeungnam University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; AVERAGE METHOD; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HOT SPOT METHOD; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABELING INDEX; LUMINAL BREAST CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHODOLOGY; PREDICTIVE VALUE; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; BREAST TUMOR; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; PATHOLOGY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; REPRODUCIBILITY OF RESULTS;

EID: 85012202197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172031     Document Type: Article

References (28)

1. 1Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry. 1991; 12(1):42-9. Epub 1991/01/01. doi: 10. 1002/cyto.990120107 PMID: 1999122
2. de Azambuja E, Cardoso F, de Castro G Jr., Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96(10):1504-13. Epub 2007/04/25. doi: 10.1038/sj.bjc.6603756 PMID: 17453008
3. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10):736-50. Epub 2009/05/14. doi: 10.1093/jnci/djp082 PMID: 19436038
4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes -dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. doi: 10.1093/annonc/mdr304 PMID: 21709140
5. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. Epub 2013/08/07. doi: 10.1093/annonc/mdt303 PMID: 23917950
6. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies -improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology: official journal of the European Society for Medical Oncology. 2015; 26(8):1533-46.
7. Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014; 2 (6):1062-8. Epub 2014/10/04. doi: 10.3892/mco.2014.400 PMID: 25279198
8. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103(22):1656-64. Epub 2011/10/01. doi: 10.1093/jnci/djr393 PMID: 21960707
9. Yamamoto S, Chishima T, Mastubara Y, Adachi S, Harada F, Toda Y, et al. Variability in measuring the Ki-67 labeling index in patients with breast cancer. Clin Breast Cancer. 2015; 15(1):e35-9. Epub 2014/12/03. doi: 10.1016/j.clbc.2014.09.005 PMID: 25445422
10. Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, et al. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS One. 2015; 10(4):e0123435. Epub 2015/04/18. doi: 10.1371/journal.pone.0123435 PMID: 25885288
11. Shui R, Yu B, Bi R, Yang F, Yang W. An interobserver reproducibility analysis of ki67 visual assessment in breast cancer. PLoS One. 2015; 10(5):e0125131. Epub 2015/05/02. doi: 10.1371/journal.pone. 0125131 PMID: 25932921
12. Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, et al. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015; 28(6):778-86. doi: 10.1038/modpathol. 2015.38 PMID: 25698062
13. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013; 105(24):1897-906. Epub 2013/11/10. doi: 10.1093/jnci/djt306 PMID: 24203987
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25(1):118-45. Epub 2006/12/13. doi: 10.1200/JCO.2006.09.2775 PMID: 17159189
15. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784-95. Epub 2010/04/21. doi: 10.1200/JCO.2009.25.6529 PMID: 20404251
16. Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, et al. A Majority of Low (1- 10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors. J Cancer. 2014; 5 (2):156-65. Epub 2014/02/25. doi: 10.7150/jca.7668 PMID: 24563670
17. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(7):729-34. Epub 2012/02/01.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45. Epub 1988/09/01. PMID: 3203132
19. Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y, et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast cancer. 2015; 22(1):71-8. doi: 10.1007/s12282-013-0455-5 PMID: 23479208
20. Mu K, Li L, Yang Q, Yun H, Kharaziha P, Ye DW, et al. A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer. Annals of diagnostic pathology. 2015; 19(4):243-8. doi: 10.1016/j.anndiagpath.2015.05.002 PMID: 26049669
21. Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, et al. A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer. Oncology. 2016; 90(1):43-50. doi: 10.1159/000441525 PMID: 26613521
22. Chung YR, Jang MH, Park SY, Gong G, Jung WH. Interobserver Variability of Ki-67 Measurement in Breast Cancer. J Pathol Transl Med. 2016; 50(2):129-37. Epub 2016/02/16. doi: 10.4132/jptm.2015. 12.24 PMID: 26875758
23. Leung SC, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. npj Breast Cancer. 2016; 2:16014.
24. Sato K, Miyashita M, Ishida T, Suzuki A, Tada H, Watanabe G, et al. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers. Breast Cancer. 2016; 23(2):310-7. Epub 2014/11/09. doi: 10.1007/s12282-014-0575-6 PMID: 25380989
25. Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, et al. Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One. 2014; 9(8):e95629. Epub 2014/08/30. doi: 10.1371/journal.pone.0095629 PMID: 25170613
26. Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2014; 27(4):554-61. Epub 2013/09/21. doi: 10.1038/modpathol.2013.153 PMID: 24051696
27. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31 (2):203-9.
28. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2013; 24(3):661-8. Epub 2012/10/02. doi: 10.1093/annonc/mds430 PMID: 23022996